Journal
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY
Volume 31, Issue 5, Pages 730-745Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.berh.2018.05.002
Keywords
Mesenchymal stromal cells; Osteoarthritis; Cell therapy; Encapsulation; Biomaterials
Categories
Funding
- Inserm
- Research on OsteoArthritis Diseases network (ROAD network)
- Arthritis Foundation
- research program Longevite Mobilite Autonomie from the Pays de la Loire region
- Societe Francaise de Rhumatologie (SFR)
Ask authors/readers for more resources
Osteoarthritis (OA) is a degenerative and inflammatory joint disease that affects the cartilage, subchondral bone, and joint tissues. Although current drug therapies can provide a degree of symptomatic relief from pain, they fail to prevent joint damage. Mesenchymal stem/stromal cells (MSCs) have generated significant interest in terms of medical applications because they exert their therapeutic properties by secretion of bioactive factors that have potent immunomodulatory, antiapoptotic, antifibrotic, and anti-inflammatory effects. However, intra-articular injection of MSCs has major limitations including cell death upon injection and massive leakage from the injection site. Encapsulation of MSCs has therefore been developed as a way to overcome these limitations and to deliver therapeutic bioactive factors in several pathologies. In this review, we first briefly highlight the main therapeutic properties of MSCs and their applications in OA treatment. We then focus on MSC encapsulation and the current advances this strategy offers for the treatment of OA. (C) 2018 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available